基于PD⁃1/PD⁃L1联合治疗在前列腺癌中的研究进展

Research progress of PD⁃1/PD⁃L1 in prostate cancer immunotherapy

前列腺癌是男性第二大常见癌症,也是男性癌症死亡的第五大原因,其传统治疗方法包括根治性前列腺癌切除术、化学治疗、雄激素剥夺治疗等,虽然起初有治疗反应,但有部分患者最终会进展到去势抵抗性前列腺癌(castration-resistant prostate cancer,CRPC)。人体免疫系统虽然能发挥监测功能,及时杀死肿瘤细胞,但肿瘤细胞在演变过程中也随之表达PD-L1,其与T细胞上的PD-1结合,能抑制T细胞功能,最终诱导免疫逃逸。对PD-1/PD-L1在前列腺癌免疫逃逸机制中的深入研究,可能对往后将基于PD-1/PD-L1的免疫治疗应用于前列腺癌治疗提供新的治疗策略。本文将对PD-1/PD-L1在前列腺癌免疫治疗中的最新研究进展作一综述。

Prostate cancer is the second most common cancer in men and the fifth leading cause of cancer deaths in men.Although there is an initial response to traditional treatments which include radical prostatectomy,chemotherapy,androgen deprivation therapy,and so on,some patients eventually progress to castration-resistant prostate cancer.The human immune system can perform a monitoring function to kill tumor cells promptly,however,tumor cells also express PD-L1 as they evolve,which binds to PD-1 on T cells and can inhibit T cell function,ultimately inducing immune evasion.The in-depth study of PD-1/PD-L1 in the mechanism of immune evasion in prostate cancer may provide new therapeutic strategies for the future application of PD-1/PD-L1-based immunotherapy in prostate cancer treatment.In this paper,we will review the latest research progress of PD-1/PD-L1 in prostate cancer immunotherapy.